Qiagen Licenses Biomarker IP from Johns Hopkins | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen said today that its DxS subsidiary has licensed a biomarker from Johns Hopkins University that it plans to use to develop PCR-based companion diagnostic tests for cancer.

Studies have shown that the PI3K gene that Qiagen licensed has mutations that could serve as predictive biomarkers for the success of some treatments for patients with lung, breast, colorectal, and other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.